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Abstract
Background: Oral squamous cell carcinoma (OSCC) constitutes a group of tumors that exhibit heterogeneous
biology, histopathology, and clinical behaviors.
Case presentation: A 73-year-old male had a whitish leukoplakia-like lesion around inflamed peri-implant area
(#42, #43, and #44), and this lesion had transformed to OSCC within 3 years. He underwent mass resection, selective
neck dissection, and reconstructive surgery. To detect any carcinogenesis progression, we examined the removed
tumor tissue as well as the patient’s preoperative and postoperative sera to identify causative oncogenic proteins
using immunoprecipitation high-performance liquid chromatography (IP-HPLC).
Conclusions: The protein expression levels of p53, E-cadherin, β-catenin, MMP-10, HER2, NRAS, Met, HER2, and ERb
were significantly lower in the serum collected on postoperative day 10 than in the preoperative serum, and if
these proteins are consistently not elevated in the serum 3 months after surgery compared with the preoperative
serum, these proteins can be potential oncogenic proteins. However, we also found that the serum extracted
3 months after the operation had elevated levels of oncogenic proteins compared with that of the preoperative
and 10-day postoperative serum indicating the possibility of tumor recurrence. At postoperative follow-up period,
ipsilateral neck metastasis and second primary lesion were found and additional surgery was performed to the
patient. IP-HPLC using the patient’s serum shows the possibility of oncogenic protein detection. However, follow-up
IP-HPLC data is needed to find out patient-specific prognostic factors.
Keywords: Oral squamous cell carcinoma (OSCC), Immunoprecipitation high-performance liquid chromatography
(IP-HPLC), Oncogenic protein, Peri-implant oral malignancy (PIOM)
Background
Squamous cell carcinoma (SCC) is the most serious
malignant tumor that frequently invades adjacent orofa-
cial structures and spreads to cervical lymph nodes.
Clinical and pathological behaviors of oral squamous cell
carcinoma (OSCC) are highly variable in terms of oral
ulceration, bone destruction, infiltrative growth, and
tumor metastasis [1–3]. Treatment modalities can be de-
cided based on clinical staging, pathologic diagnosis,
general status of patient, or anatomic region of tumor
presence. Clinical staging can be determined during the
initial work-up, including a clinical exam, radiological
exam with dental panorama, ultrasonography, computed
tomography (CT), magnetic resonance imaging (MRI),
and positron emission tomography-computed tomog-
raphy (PET-CT). One of the primary treatments for
OSCC is radical excision with or without adjuvant
chemoradiotherapy, which has proven to be effective for
locoregional control. Nevertheless, biomarkers involved
in tumor recurrence and prognosis have not been identi-
fied for OSCC [4, 5]. Clinically, detection of tumor
markers in the serum is easy and non-invasive. Squa-
mous cell carcinoma antigen (SCC-Ag), cytokeratin, are
well-known tumor-related markers [6]. We assumed that
protein markers produced by the tumor can be reduced
by tumor ablative surgery. The serum of cancer patient
was used for protein analysis.
Immunoprecipitation high-performance liquid chro-
matography (IP-HPLC) is a type of protein detection
method that is based on real antigen-antibody reaction
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in a phosphate-buffered saline (PBS) solution, followed
by purification using protein A/G-conjugated agarose
beads. Although its procedures are simple and easy to
apply to most biological samples, IP-HPLC can yield a
minimum error range by using micro-beads instead of
small wells to mimic the enzyme-linked immunosorbent
assay (ELISA) [7, 8]. The patient’s serum was collected
before his operation, 10 days after the operation, and
3 months after the operation. Each sample was analyzed
via IP-HPLC, which has been improved in terms of data
accuracy and statistical analysis.
Case presentation
A 73-year-old male patient was referred from his general
dentist for further evaluation of whitish lesion on the
attached gingiva and associated peri-implantitis. A pano-
ramic view shows generalized alveolar bone loss and
calculi deposition in the peri-implant region (#42, #43,
#44), and the right mandibular anterior and premolar
area showed peri-implant crestal bone loss. Laboratory
findings were within normal limits. Other several
oncogenic protein elevation situations, including tobacco
and/or alcohol use, no nutritional deficiencies, no
findings of ionizing radiation exposure, no immunodefi-
ciency or immunosuppressant, and other removal pros-
thesis irritations, were all excluded. A whitish lesion was
excised, and the specimen was sent to an oral patholo-
gist. The contaminated implant surface was treated with
a laser. The pathologic diagnosis was confirmed as oral
candidiasis. The patient underwent laser treatment three
times to treat the peri-implantitis lesion. One year later,
his implant of #42, #43, and #44 area were removed due
to peri-implantitis at the local clinic. From the referral
letter of local clinic, the implant system was internal fric-
tional connection type having a SLA surface, which was
installed for more than 10 years.
About 3 years later after the laser operation, a bulging
mass was identified on the lingual side of #43 and #44
area. An incisional biopsy was performed and was
diagnosed as a SCC (Fig. 1). Further work-up was per-
formed including lab, chest X-ray, ECG, MRI, contrast
CT, PET-CT, and neck sonography. The patient was
diagnosed with cT4aN2cM0 stage IVA according to the
TNM staging system proposed by the American Joint
Committee on Cancer (AJCC, 2018). He was immedi-
ately scheduled for an operation that included selective
neck dissection, mass resection with marginal mandibu-
lectomy, and reconstruction with a radial forearm free
flap. The final pathologic report was well-differentiated
squamous cell carcinoma, with a 1.5 × 2.0-cm size of
tumor, no metastasis to any of the 27 regional lymph
nodes, and clear surgical resection margin. Vascular and
perineural invasions were not observed; thus, he was
diagnosed as pT1N0M0, stage I. Especially, rather than
on the interface between the implant and the bone,
tumor cells occurred on the surface of the mucosal soft
tissue first and penetrated deeply along the implant
threads. Neither adjuvant radiotherapy nor chemother-
apy was not administered to the patient.
A metastatic lymph node was found at the right
ipsilateral level IV on enhanced CT taken 4 months
postoperatively. Selective neck dissection, including right
level IV, was performed, and a newly developed suspi-
cious for malignant lesion was found on the right
maxilla. The patient’s maxilla lesion was confirmed for
SCC by incisional biopsy; therefore, he underwent an
Fig. 1 Clinical photos of the patient. a Initial visit; b peri-implantitis treatment with laser; c after 3-times laser treatment; d 5 months after initial
visit; e 3 years after initial visit, the lesion was confirmed OSCC by incisional biopsy; f preoperative view show bulging tumor mass to lingual side
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additional surgery 13 days after second selective neck
dissection (Fig. 2). The final pathologic report on the
maxillary lesion was well-differentiated SCC with a 2.0 ×
1.4-cm size of tumor; depth of invasion was 0.7 cm.
Involvement of underlying bone was present. Surgical
resection margins were clear.
The surgically removed specimens were fixed in 10%
neutral buffered formalin, processed following a routine
protocol, and serial micro-sections with different anti-
sera were also prepared for immunohistochemical stain-
ing. All data files of the patient were selected from the
files of the Department of Oral and Maxillofacial
Surgery, Seoul National University Dental Hospital
under the approval of the institutional review board of
Seoul National University (S-D20170026).
IP-HPLC analysis for the protein extract obtained from
the serum of patients
The patient’s blood was collected preoperatively, 10 days
postoperatively, and 3 months postoperatively. After
precipitation at room temperature, the samples were
centrifuged at 4000 rpm for 20min. Only the supernants
were collected and mixed with lysis buffer and used for
IP-HPLC. We applied 100 μg of each protein extract to
the immunoprecipitation procedure using a protein A/G
agarose column (Amicogen Co., Korea). The protein A/
G agarose columns were separately pre-incubated with
1 μg of each of the 20 different antisera, including p53,
muc1, muc4, TGF-β1, survivin, Wnt1, E-cadherin, β-
catenin, matrix metalloproteinase (MMP)-3, MMP-10,
TNFα, HER1, HER2, PAI-1, NRAS, KRAS, CEA, Met,
FASL, and ERb. Briefly, the protein samples were mixed
with 5 ml of binding buffer (150 mM NaCl, 10 mM Tris
pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium
vanadate, 0.2 mM PMSF, and 0.5% NP-40) and incu-
bated in the protein A/G agarose columns at 10 °C for 1
h. The columns were placed on a rotating stirrer during
the incubation. After washing each column with a
sufficient amount of PBS solution (pH 7.3, 137 mM
NaCl, 2.7 mM KCl, 43 mM Na2HPO4-7H2O, and 1.4
mM KH2PO4), the target protein was eluted with 150 μl
of IgG elution buffer (Pierce Co., USA). The immuno-
precipitated proteins were analyzed by HPLC (1100
series®, Agilent, USA) using a reverse-phase column and
micro-analytical detector system (SG Hightech Co.,
Korea), operated with a 0.15-M NaCl and 20% aceto-
nitrile solution at 0.4 mL/min for 30 min, and analyzed
via UV spectroscopy at 280 nm. In the IP-HPLC results,
the sample protein peak areas obtained from the HPLC
analysis in the negative control were used to eliminate
the antibody peak area (mAU*s) [7–9]. To compare
preoperative and postoperative serum protein, the
protein peak area values were proportionally normalized
by the α-tubulin value and plotted as a bar.
IP-HPLC analysis of extracted tumor protein
Protein extracts were prepared from tumor tissue,
100 μg each protein extract to the immunoprecipitation
procedure using a protein A/G agarose column. The
protein A/G agarose columns were individually pre-
incubated with 1 μg of each of the 9 different antisera,
including TNFα, NRAS, HER2, Met, E-cadherin, p53,
survivin, TGF-β1, and NFκB. Briefly, the protein samples
were mixed with 5 ml of binding buffer (150 mM NaCl,
10 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM
sodium vanadate, 0.2 mM PMSF, and 0.5% NP-40) and
incubated in the protein A/G agarose columns at 10 °C
for 1 h. To compare the normal gingiva and SCC tissue
protein, the protein peak area values were proportionally
normalized by the α-tubulin value and plotted as a bar.
Laboratory analysis
Routine laboratory results were collected, including
complete blood cell counts (CBC) with differential
Fig. 2 Clinical signs showed the recurrence of tumor. a Newly developed maxillary peri-implant oral malignancy lesion, b CT findings suspected
of metastatic lymph node
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count, C-reactive protein (CRP) levels, and erythrocyte
sedimentation rate (ESR). A modest elevation in the
plasma CRP in the range observed in apparently healthy
individuals is a strong predictor of future vascular events
[10]. Chen et al. [11] reported the presence of elevated
preoperative serum CRP level (> 5.0 mg/L) is an inde-
pendent prognostic indicator of oral cancer. The results
from the blood sample tests were compared from the
first visit, preoperatively, postoperatively, and at the time
of recurrence.
IP-HPLC analysis from the serum of patients
The IP-HPLC analyses revealed that p53, E-cadherin, β-
catenin, MMP-10, HER2, NRAS, Met, and ERb had
decreased at postoperative day 10. Other protein
markers related to oncogenic signaling were increased at
postoperative day 10. This suggests that oncogenic
proteins, such as p53, E-cadherin, β-catenin, MMP-10,
HER2, NRAS, Met, and ERb were released from the
primary tumor; therefore, serum levels of these onco-
genic proteins decreased after tumor-ablative surgery
(Fig. 3). In 3 months postoperatively using the patient’s
serum, all oncogenic protein markers were elevated and
tumor recurrence or metastasis was suspected (Fig. 4).
IP-HPLC analysis from extracted tumor protein
IP-HPLC analyses revealed that NRAS, Met, p53, and
NFκB were overexpressed in the SCC tissue in the com-
parison of oncogenic protein levels between normal gin-
giva and SCC tissue (Fig. 5).
Fig. 3 An upper bar graph and a lower line graph comparing oncogenic protein expression profiles between preoperative and postoperative day
10 serum
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Laboratory findings
Inflammatory markers such as white blood cell count
(WBC), absolute neutrophil count (ANC), ESR, and CRP
were elevated immediately postoperatively. CRP was not
conducted preoperatively, and so, that data cannot be
compared to other time points; however, CRP levels had
not changed significantly before and after the second
operation (right level IV selective neck dissection,
Additional file 1: Figure S1). Notably, ESR counts were
elevated in the preoperative period, as determined when
a malignant lesion was confirmed by incisional biopsy
and compared with a sample taking at the first visit.
That indicates that some inflammatory reactions can
affect the potential of malignant transformation.
Perioperative changes in the RBCs, hemoglobin,
hematocrit showed that the levels were decreased during the
post-surgery, but tended to recover over time (Add-
itional file 2: Figure S2). The proportion of segmented neu-
trophils increased immediately after surgery, which are
characteristic cells of acute inflammatory reactions, because
they moved to surgical wound immediately after trauma in
several minutes. The graphed curves of lymphocyte,
Fig. 4 An upper bar graph and a lower line graph comparing oncogenic protein expression profiles between preoperative, postoperative 10 days,
and postoperative 3 months after first ablation surgery
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monocyte, eosinophil, and basophil levels showed opposite
trends from the segmented neutrophil levels (Add-
itional file 3: Figure S3).
Discussion
The peri-implant leukoplakia lesion and peri-implantitis
transformed to SCC over several years in this patient;
oral cancers may be preceded by potentially malignant
disorders, recognizable mucosal diseases such as local-
ized leukoplakia or erythroplakia, or other wide-spread
conditions, all of which harbor a considerably increased
risk for SCC [12].
Peri-implantitis is a common long-term complication
of dental implant. Clinical characteristics of peri-
implantitis include swelling, erythema, and often suppur-
ation. Marginal bone loss and pocket formation are
typical. The etiology is multifactorial and not fully
understood, with bacterial factors, surgical factors, im-
plant surface characteristics, prosthetic design, and
genetic predisposition suggested as contributing factors.
A review of several small case series included analyses of
biopsy material from peri-implantitis, reported hyperpla-
sia, and ulceration of pocket epithelium and presence of
a mixed population of inflammatory cells [13]. A study
of 117 biopsies from peri-implantitis cases reported that
nearly 50% of cases did not exhibit simple inflammatory
changes. Instead, other potentially aggressive lesions,
such as pyogenic granuloma, giant cell granuloma, or
Actinomyces-related inflammation were diagnosed [14].
A literature review of retrospective analyses of cases
from 2000 to 2016 revealed 47 reported cases of oral
malignancy involving dental implants. Peri-implant ma-
lignancies were primary tumors in 29 cases (61.7%), re-
current or second primary tumors in 11 cases (23.4%),
and metastasis from distant tumors in 4 cases (8.5%).
Recognized risk factors for oral cancer included poten-
tially malignant conditions (erythroplakia, leukoplakia,
oral lichen planus, or proliferative verrucous leukoplakia)
in 21 cases (44.7%). There is very little evidence that
links dental implant and cancer. Regarding orthopedic
stainless-steel plates, an annual prevalence increase of
0.12% per year for osteosarcoma has been reported and
is suggested to be a result of corrosion caused by surface
imperfections and chronic inflammation [15]. No such
data exist regarding titanium dental implants. Only a
single in vitro experiment found that exposure to titan-
ium particles yielded a dose-responsive induction of
chromosomal instability in human fibroblasts, similar to
that induced by heavy metal and low-dose radiation ex-
posure. There are conflicting results in the literature,
with no clear evidence that corrosion material (as op-
posed to titanium oxide nanoparticles) can play a role in
carcinogenesis [16, 17]. However, peri-implant malig-
nancy is not as rare as currently reported and may be
responsible for 1.5% of oral malignancy cases [18].
Numerous candidate biomarkers have been evaluated in
blood, tumor, and saliva specimens, which yields hopes
elucidating disease pathways and improved prognosis pre-
diction. Several classes of molecules of particular interest
have been evaluated, including MMPs, interleukins,
proangiogenic and antiangiogenic factors, growth factors,
and tumor factors [19]. In this study, we evaluated the
oncogenic proteins using preoperative and postoperative
serum and tumor tissue via IP-HPLC. Serum samples
were collected preoperatively, 10 days postoperatively (be-
fore recurrence detection), and 3 months postoperatively
(between the first tumor ablation surgery and the second
dissection of metastatic lymph node). p53, E-cadherin, β-
catenin, MMP-10, HER2, NRAS, Met, and ERb were lower
in the serum collected on the postoperative 10 days.
Fig. 5 A line graph (a) and a bar graph (b) comparing oncogenic protein expression profiles between normal gingiva and SCC tissue from the
first ablation surgical specimen
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NRAS, Met, p53, and NFκB were overexpressed in the
tumor compared with the normal gingiva. Therefore, we
considered oncogenic proteins including p53, E-cadherin,
β-catenin, MMP-10, HER2, NRAS, Met, and ERb as prog-
nostic markers in this tumor. p53 tumor suppressor gene
is essential in regulating cell cycle progression, differenti-
ation, DNA repair, and apoptosis. p53 level in saliva was
shown to be significantly higher in patients with OSCC
[20]. Cadherin is a superfamily of calcium-dependent
transmembrane proteins that act as adhesion molecules
with roles in a variety of processes including development,
morphogenesis, organogenesis, and carcinogenesis. The
cadherin switch is probably necessary for increased mobil-
ity but not for morphological changes that occur in
epithelial-mesenchymal transition (EMT) [21]. However,
controversy exists, some studies showing that a simple
loss of E-cadherin is responsible for OSCC progression
[22].
In Wnt signaling pathways, the β-catenin pathway is
one of the major oncogenic pathways; deregulation of
the β-catenin pathway and consequent overactivity of β-
catenin may contribute to oral SCC progression. More
recently, it has been shown that the activation of the β-
catenin pathway is correlated with EMT and invasive-
ness of cancer cells [23]. Epidermal growth factor family
of transmembrane tyrosine kinase receptors includes
homodimers or heterodimers of four receptors: EGFR,
HER2, HER3, and HER4. The role of HER2 in OSCC
has failed to come up with definitive involvement [24];
however, in this study, the serum level of HER2 was de-
creased at postoperative day 10, showing downregulation
in the tumor IP-HPLC. MMPs are a 24-member family
of extracellular proteins subdivided into different groups
based on structural characteristics and substrate specifi-
city and include the following: collagenases, gelatinases,
stromelysins, and membrane-type MMPs.
Cancer cells degrade the extracellular matrix facilitat-
ing migration and metastasis. OSCC progression is likely
to be maintained by the stromelysins as tumor margins
show expression of MMP-3, whereas MMP-10 and
MMP-11 are linked to tumor differentiation and local
invasion [25]. The Met tyrosine kinase is a heterodimeric
cell-surface receptor consisting of a disulphide-linked
145-kDa transmembrane β-chain and an extracellular
50-kDa α-chain. Its only known agonistic ligand is hep-
atocyte growth factor (HGF). The cellular effect induced
by HGF via Met includes enhanced proliferation, stimu-
lation of cell movement and migration, and a complex
regulation of cell survival and pro-apoptotic effects, de-
pending on the biological context [26]. In OSCC, Met
expression has been associated with cisplatin resistance
and a strong metastatic ability in vivo, as well as a poor
patient prognosis [27]. Ras gene family mutations are
frequently associated with the development of cancer
with each tumor type showing a predisposition to one of
isoforms, e.g., HRAS, KRAS, and NRAS. Activated RAS
facilitates several signaling cascades including PI3K/AKT
and MAPK. Activated AKT encourages cell survival
through inhibition of apoptosis and activation of NFκB
[24, 27]. NFκB is a nuclear transcription factor that par-
ticipates in cellular functions such as proliferation, sur-
vival, and apoptotic processes and also associated with
inflammation, immunoregulation, and cancer. Some ef-
fectors of activated NFκB include chemokines and cyto-
kines that sustain growth and confer advantages
allowing tumor growth in the microenvironment
through stimulation of inflammatory cell infiltration and
angiogenesis. NFκB is also responsible for the enhanced
expression of MMP degradative enzymes in many tu-
mors, which may be linked to the ability of tumors to
metastasize through the breakdown of supporting struc-
tures [28].
Overexpression of NRAS, Met, p53, and NFκB in
tumor IP-HPLC revealed the potential of proliferation
and metastasis. However, all of the oncogenic proteins
evaluated in this study were increased in the serum at
the 3-month postoperative period. Further IP-HPLC
analysis using the patient’s serum is required for identifi-
cation of prognostic markers. The IP-HPLC results from
the serum samples allowed for early detection in tumor
recurrence in this patient, and enhanced CT images,
which were taken 4 months postoperatively, revealed a
metastatic lymph node at ipsilateral level IV. Second pri-
mary lesion was also found on the maxillary gingiva
around implant.
In this study, we showed that long-term inflammation,
such as peri-implantitis, can contribute to premalignant
mucosa disease which can subsequently change to ma-
lignancy. There was inevitable limitation in the way that
we conduct simple comparison of preoperative and the
10-day postoperative sera of the patient to identify
serum-based prognostic markers. IP-HPLC data from a
longer postoperative follow-up period are needed to bet-
ter understand the overall tendency of tumor behavior.
Therefore, clinicians have to closely follow-up with cases
of premalignant lesion, especially in the peri-implantitis
cases.
Conclusions
The protein expression levels of p53, E-cadherin, β-
catenin, MMP-10, HER2, NRAS, Met, HER2, and ERb
were significantly lower in the serum collected on
postoperative day 10 than in the preoperative serum.
At postoperative follow-up period, IP-HPLC using pa-
tient’s serum showed the possibility of oncogenic pro-
tein profiles detection. Follow-up IP-HPLC data is
needed to find out patient-specific prognostic
markers.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40902-019-0235-z.
Additional file 1: Figure S1. Changes in the serum markers which can
be used for evaluation of degree of inflammation showing WBC (A), ANC
(B), ESR (C), and hs-CRP (D). IP-HPLC 1 indicated the timing of the serum
collected for IP-HPLC analysis at postoperative 10 days. IP-HPLC 2 indi-
cated the timing of the serum collected for IP-HPLC analysis at postoper-
ative 3 months. The result of IP-HPLC 2 described the recurrence of
tumor, and after enhanced CT taking, the selective neck dissection was
performed to remove of metastatic lymph node.
Additional file 2: Figure S2. Changes of component of complete
blood cell counts showing RBC (A), Hb (B), Hct (C), and PLT (D).
Additional file 3: Figure S3. Changes of differential count of CBC
showing segmental neutrophil (A), lymphocyte (B), monocyte (C),
eosinophil (D), and basophil (E).
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